Diabetes is a serious complex condition which can affect the entire body. Diabetes occurs due to inadequate secretion of insulin inside the pancreas. Insulin secreted by pancreas in hormone made by beta cell which is responsible for the conversion of glucose from food to energy. There are different types of diabetes, all type diabetes serious and complex body condition. The three main types of diabetes are type 1, type 2 and gestational diabetes.Type 2 is prolonged condition of body which inadequate production of insulin by pancreas to convert the glucose from food energy. Type 2 diabetes is strongly associated with genetic and family related risk factors. In general, type 2 diabetes develop occur in adults after the age of 45 but nowadays the prevalence of children and young adults suffering from diabetes are is increasing. Some of the major symptom of type 2 diabetes are excessively thirstiness, feeling tired and lethargic, always feeling hungry, require more time to cure heals and others. Diabetes is non-curable disease and it can only be controlled by changing life style and medication. Medication given by pill or injections to increase the level of insulin in human body. Insulin are injected by using syringe and insulin pens.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/16504
Increasing prevalence of diabetes worldwide is the primary factor driving the growth of inadequately controlled type 2 diabetes treatment market. Rising geriatric population and change in life style of people is also responsible for the rapid increasing prevalence of diabetes globally. Increasing initiative by NGO for the treatment of diabetes among the people will boost the growth of this market. Technological advance leads to development of highly improved drugs for the treatment of diabetes will propel the growth of inadequately controlled type 2 diabetes treatment market. On other hand, unfavorable reimbursement policies will restrain the growth of inadequately controlled type2 diabetes treatment market. Besides that, high cost drug and chances of technical error will also impact the growth of inadequately controlled type 2 diabetes treatment market.
The inadequately controlled type 2 diabetes treatment market is expected show robust growth over the forecast period due to rise geriatric population suffering from type 2 diabetes. Type 2 diabetes include 85-90% diabetes case globally. According to 7th edition of the International Diabetes Federation’s (IDF) 415 million people are suffering from diabetes worldwide. Same study also stated that China ranked highest number of people with diabetes which over 100 million people suffering from diabetes. Currently there are very few drugs are available in the market for the treatment of inadequately controlled type 2 diabetes.
Some of the players across the value chain of inadequately controlled type 2 diabetes treatment market are Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company and others.